Back to News
Market Impact: 0.3
Sandoz Issues Mid-term Outlook For 2025-2030; Unveils Bio100 Ambition
Source: Nasdaq
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Sandoz reaffirmed its existing mid-term outlook through 2028 and introduced 2025-2030 targets for mid-to-high single-digit average annual net-sales growth at constant currencies. The company also set a core EBITDA-margin target beginning at 25%, though the article text is truncated before the full margin range is provided. The reaffirmed and extended targets signal confidence in sustained growth and profitability.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SDZ0.55
More News
- What next for France as riots rattle markets? Three questions facing investors ahead of more protests
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage